Repligen Corporation (RGEN)
Automate Your Wheel Strategy on RGEN
With Tiblio's Option Bot, you can configure your own wheel strategy including RGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RGEN
- Rev/Share 11.5044
- Book/Share 35.3773
- PB 3.4576
- Debt/Equity 0.3443
- CurrentRatio 6.7927
- ROIC -0.0128
- MktCap 6872316792.0
- FreeCF/Share 2.0953
- PFCF 58.4401
- PE -270.5725
- Debt/Assets 0.2397
- DivYield 0
- ROE -0.0127
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RGEN | Wolfe Research | Peer Perform | Outperform | -- | $160 | April 29, 2025 |
| Initiation | RGEN | Evercore ISI | -- | In-line | -- | $155 | March 18, 2025 |
| Initiation | RGEN | TD Cowen | -- | Buy | -- | $200 | Feb. 10, 2025 |
| Initiation | RGEN | Canaccord Genuity | -- | Hold | -- | $165 | Dec. 17, 2024 |
| Initiation | RGEN | Wells Fargo | -- | Overweight | -- | $180 | Aug. 28, 2024 |
News
Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Negative
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Read More
Repligen Corporation to Present at Upcoming May Investor Conferences
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.
Read More
QGEN or RGEN: Which Is the Better Value Stock Right Now?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Read More
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
Read More
Repligen Reports First Quarter 2025 Financial Results
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.
Read More
GMAB or RGEN: Which Is the Better Value Stock Right Now?
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Genmab A/S Sponsored ADR (GMAB) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?
Read More
Repligen: Ongoing Bioprocessing Market Recovery
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
I reiterate a 'buy' rating for Repligen with a one-year price target of $175 per share, driven by strong bioprocessing market recovery. Repligen reported 3% organic revenue growth and 13% growth in non-COVID business, with record-high order intakes since Q2 FY22. The acquisition of 908 Devices' bioprocessing analytics portfolio enhances Repligen's process analytical technology, adding significant value to its offerings.
Read More
908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth
Published: March 04, 2025 by: Benzinga
Sentiment: Positive
On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.
Read More
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive
RGEN reports decent fourth-quarter results and issues guidance for 2025.
Read More
Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Repligen Corporation (NASDAQ:RGEN ) Q4 2024 Earnings Call Transcript February 20, 2025 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital Markets Matt Hewitt - Craig Hallum Subbu Nambi - Guggenheim Securities Justin Bowers - Deutsche Bank Paul Knight - KeyBanc Capital Doug Schenkel - Wolfe Research Operator …
Read More
Repligen (RGEN) Beats Q4 Earnings Estimates
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago.
Read More
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET
Read More
About Repligen Corporation (RGEN)
- IPO Date 1986-04-29
- Website https://www.repligen.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Olivier Loeillot
- Employees 1778